Benzinga's Top Initiations

Analysts at Barclays initiated coverage on

with a Overweight rating. The target price for Chemours is set to $24. Chemours' shares closed at $16.51 on Thursday. Analysts at RBC Capital initiated coverage on

with a Outperform rating. The target price for Epizyme is set to $40. Epizyme shares closed at $22.71 on Thursday. Analysts at Stifel Nicolaus initiated coverage on

with a Buy rating. The target price for Biotie Therapies is set to $30. Biotie Therapies' shares closed at $18.39 on Thursday. Jefferies initiated coverage on

with a Buy rating. The target price for Axovant Sciences is set to $31. Axovant Sciences' shares closed at $19.19 on Thursday. Analysts at Barclays initiated coverage on

with a Equal-weight rating. The target price for NiSource is set to $17. NiSource shares closed at $16.99 on Thursday. Summit Research initiated coverage on

with a Buy rating. The target price for Imperva is set to $75. Imperva shares closed at $67.00 on Thursday. Analysts at Bernstein initiated coverage on

with a Outperform rating. NextEra Energy shares closed at $100.22 on Thursday. Bank of America initiated coverage on

with a Buy rating. The target price for InterXion Holding is set to $31. InterXion Holding's shares closed at $27.95 on Thursday. Analysts at Rodman & Renshaw initiated coverage on

with a Buy rating. The target price for Second Sight Medical is set to $21. Second Sight Medical shares closed at $14.05 on Thursday. JP Morgan initiated coverage on

with a Neutral rating. The target price for GasLog is set to $21. GasLog shares closed at $19.16 on Thursday.